The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance

References

• Abe K, Bridges AS, Brouwer KL. (2009). Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. Drug Metab Dispos 37:447–452.
   PubMed Web of Science ®Google Scholar
• Akamine Y, Miura M, Sunagawa S, Kagaya H, Yasui-Furukori N, Uno T. (2010). Influence of drug-transporter polymorphisms on the pharmacokinetics of fexofenadine enantiomers. Xenobiotica 40:782–789.
   PubMed Web of Science ®Google Scholar
• Amundsen R, Christensen H, Zabihyan B, Asberg A. (2010). Cyclosporine A, but not tacrolimus, shows relevant inhibition of organic anion-transporting protein 1B1-mediated transport of atorvastatin. Drug Metab Dispos 38:1499–1504.
   PubMed Web of Science ®Google Scholar
• Asberg A. (2003). Interactions between cyclosporin and lipid-lowering drugs: Implications for organ transplant recipients. Drugs 63:367–378.
   PubMed Web of Science ®Google Scholar
• Ayrton A, Morgan P. (2001). Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 31:469–497.
   PubMed Web of Science ®Google Scholar
• Ayrton A, Morgan P. (2008). Role of transport proteins in drug discovery and development: A pharmaceutical perspective. Xenobiotica 38:676–708.
   PubMed Web of Science ®Google Scholar
• Backman JT, Honkalammi J, Neuvonen M, Kurkinen KJ, Tornio A, Niemi M, Neuvonen PJ. (2009). CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: Estimation of CYP2C8 half-life using repaglinide as an in vivo probe. Drug Metab Dispos 37:2359–2366.
   PubMed Web of Science ®Google Scholar
• Backman JT, Kyrklund C, Kivistö KT, Wang JS, Neuvonen PJ. (2000). Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 68:122–129.
   PubMed Web of Science ®Google Scholar
• Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ. (2002). Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 72:685–691.
   PubMed Web of Science ®Google Scholar
• Betts A, Atkinson F, Gardner I, Fox D, Webster R, Beaumont K, Morgan P. (2007). Impact of physicochemical and structural properties on the pharmacokinetics of a series of α1L-adrenoceptor antagonists. Drug Metab Dispos 35:1435–1445.
   PubMedGoogle Scholar
• Bi Y, Kazolias D, Duignan DB. (2006). Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport. Drug Met Disp 34:1658–1665.
   PubMed Web of Science ®Google Scholar
• Binet I, Wallnöfer A, Weber C, Jones R, Thiel G. (2000). Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A. Kidney Int 57:224–231.
   PubMed Web of Science ®Google Scholar
• Borst P, de Wolf C, van de Wetering K. (2007). Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Arch 453:661–673.
   PubMed Web of Science ®Google Scholar
• Brunham LR, Lansberg PJ, Zhang L, Miao F, Carter C, Hovingh GK, Visscher H, Jukema JW, Stalenhoef AF, Ross CJ, Carleton BC, Kastelein JJ, Hayden MR. (2011). Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J. doi:10.1038/tpj.2010.92.
   PubMed Web of Science ®Google Scholar
• Castell JV, Jover R, Martínez-Jiménez CP, Gómez-Lechón MJ. (2006). Hepatocyte cell lines: Their use, scope and limitations in drug metabolism studies. Expert Opin Drug Metab Toxicol 2:183–212.
   PubMed Web of Science ®Google Scholar
• Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ, Smolarek TA. (2005). Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos 33:537–546.
   PubMed Web of Science ®Google Scholar
• Choi MK, Jin QR, Choi YL, Ahn SH, Bae MA, Song IS. (2011). Inhibitory effects of ketoconazole and rifampin on OAT1 and OATP1B1 transport activities: Considerations on drug-drug interactions. Biopharm Drug Dispos 32:175–184.
   PubMedGoogle Scholar
• Chung JY, Cho JY, Yu KS, Kim JR, Oh DS, Jung HR, Lim KS, Moon KH, Shin SG, Jang IJ. (2005). Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther 78:342–350.
   PubMed Web of Science ®Google Scholar
• Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. (1999). OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27:866–871.
   PubMed Web of Science ®Google Scholar
• De Buck SS, Sinha VK, Fenu LA, Nijsen MJ, Mackie CE, Gilissen RA. (2007). Prediction of human pharmacokinetics using physiologically based modeling: A retrospective analysis of 26 clinically tested drugs. Drug Metab Dispos 35:1766–1780.
   PubMed Web of Science ®Google Scholar
• Deng JW, Song IS, Shin HJ, Yeo CW, Cho DY, Shon JH, Shin JG. (2008). The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: The contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics 18:424–433.
   PubMed Web of Science ®Google Scholar
• Dingemanse J, van Giersbergen PL. (2004). Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet 43:1089–1115.
   PubMed Web of Science ®Google Scholar
• EMA DDI draft guidance. (2010) Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/05/WC500090112.pdf
   Google Scholar
• Evers R, Chu XY. (2008). Role of the murine organic anion-transporting polypeptide 1b2 (Oatp1b2) in drug disposition and hepatotoxicity. Mol Pharmacol 74:309–311.
   PubMed Web of Science ®Google Scholar
• Flynn CA, Hagenbuch BA, Read GA. (2010) Losartan is a substrate of organic anion transporting polypeptide 2B1 FASEB J. 24 (meeting abstract supplement) 758.2
   Google Scholar
• Foti RS, Rock DA, Wienkers LC, Wahlstrom JL. (2010). Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation. Drug Metab Dispos 38:981–987.
   PubMed Web of Science ®Google Scholar
• Fujino H, Saito T, Tsunenari Y, Kojima J, Sakaeda T. (2004). Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors. Xenobiotica 34:961–971.
   PubMed Web of Science ®Google Scholar
• Funk C. (2008). The role of hepatic transporters in drug elimination. Expert Opin Drug Metab Toxicol 4:363–379.
   PubMed Web of Science ®Google Scholar
• Furberg CD, Pitt B. (2001). Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2:205–207.
   PubMedGoogle Scholar
• Gardner IB, Walker DK, Lennard MS, Smith DA, Tucker GT. (1995). Comparison of the disposition of two novel combined thromboxane synthase inhibitors/thromboxane A2 receptor antagonists in the isolated perfused rat liver. Xenobiotica 25:185–197.
   PubMed Web of Science ®Google Scholar
• Glavinas H, Méhn D, Jani M, Oosterhuis B, Herédi-Szabó K, Krajcsi P. (2008). Utilization of membrane vesicle preparations to study drug-ABC transporter interactions. Expert Opin Drug Metab Toxicol 4:721–732.
   PubMed Web of Science ®Google Scholar
• Gohlke P, Weiss S, Jansen A, Wienen W, Stangier J, Rascher W, Culman J, Unger T. (2001). AT1 receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin II in conscious rats. J Pharmacol Exp Ther 298:62–70.
   PubMed Web of Science ®Google Scholar
• Gui C, Hagenbuch B. (2008). Molecular determinants for substrate selectivity of OATP-1B3. FASEB J. 151:393–399.
   Google Scholar
• Gui C, Hagenbuch B. (2010). Cloning/characterization of the canine organic anion transporting polypeptide 1b4 (Oatp1b4) and classification of the canine OATP/SLCO members. Comp Biochem Physiol C Toxicol Pharmacol 151:393–399.
   PubMed Web of Science ®Google Scholar
• Gui C, Obaidat A, Chaguturu R, Hagenbuch B. (2010). Development of a cell-based high-throughput assay to screen for inhibitors of organic anion transporting polypeptides 1B1 and 1B3. Curr Chem Genomics 4:1–8.
   PubMedGoogle Scholar
• Gullestad L, Nordal KP, Berg KJ, Cheng H, Schwartz MS, Simonsen S. (1999). Interaction between lovastatin and cyclosporine A after heart and kidney transplantation. Transplant Proc 31:2163–2165.
   PubMed Web of Science ®Google Scholar
• Hagenbuch B, Meier PJ. (2004). Organic anion transporting polypeptides of the OATP/ SLC21 family: Phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch 447:653–665.
   PubMed Web of Science ®Google Scholar
• Hagenbuch B, Gui C. (2008). Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica 38:778–801.
   PubMed Web of Science ®Google Scholar
• Hamelin BA, Turgeon J. (1998). Hydrophilicity/lipophilicity: Relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 19:26–37.
   PubMed Web of Science ®Google Scholar
• Harrison A, Betts A, Fenner K, Beaumont K, Edgington A, Roffey S, Davis J, Comby P, Morgan P. (2004). Nonlinear oral pharmacokinetics of the alpha-antagonist 4-amino-5-(4-fluorophenyl)-6,7-dimethoxy-2-[4-(morpholinocarbonyl)-perhydro-1,4-diazepin-1-yl]quinoline in humans: Use of preclinical data to rationalize clinical observations. Drug Metab Dispos 32:197–204.
   PubMed Web of Science ®Google Scholar
• Hasunuma T, Nakamura M, Yachi T, Arisawa N, Fukushima K, Ijima H, Saito Y. (2003). The drug-drug interactions of pitavastatin (NK-104), a novel HMG-CoA reductase inhibitor and cyclosporine. J Clin Ther Med 19:381–389.
   Google Scholar
• Hedman M, Neuvonen PJ, Neuvonen M, Holmberg C, Antikainen M. (2004). Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. Clin Pharmacol Ther 75:101–109.
   PubMed Web of Science ®Google Scholar
• Hinton LK, Galetin A, Houston JB. (2008). Multiple inhibition mechanisms and prediction of drug-drug interactions: Status of metabolism and transporter models as exemplified by gemfibrozil-drug interactions. Pharm Res 25:1063–1074.
   PubMed Web of Science ®Google Scholar
• Hirano M, Maeda K, Shitara Y, Sugiyama Y. (2004). Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 311:139–146.
   PubMed Web of Science ®Google Scholar
• Hirano M, Maeda K, Shitara Y, Sugiyama Y. (2006). Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos 34:1229–1236.
   PubMed Web of Science ®Google Scholar
• Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, Kim RB. (2006). Drug and bile acid transporters in rosuvastatin hepatic uptake: Function, expression, and pharmacogenetics. Gastroenterology 130:1793–1806.
   PubMed Web of Science ®Google Scholar
• Hosea NA, Collard WT, Cole S, Maurer TS, Fang RX, Jones H, Kakar SM, Nakai Y, Smith BJ, Webster R, Beaumont K. (2009). Prediction of human pharmacokinetics from preclinical information: Comparative accuracy of quantitative prediction approaches. J Clin Pharmacol 49:513–533.
   PubMed Web of Science ®Google Scholar
• Houston JB. (1994). Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469–1479.
   PubMed Web of Science ®Google Scholar
• Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, Kirchgessner TG. (1999). A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 274:37161–37168.
   PubMed Web of Science ®Google Scholar
• Ichimaru N, Takahara S, Kokado Y, Wang JD, Hatori M, Kameoka H, Inoue T, Okuyama A. (2001). Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. Atherosclerosis 158:417–423.
   PubMed Web of Science ®Google Scholar
• Ieiri I, Higuchi S, Sugiyama Y. (2009). Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: Implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin Drug Metab Toxicol 5:703–729.
   PubMed Web of Science ®Google Scholar
• Igel M, Sudhop T, von Bergmann K. (2001). Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur J Clin Pharmacol 57:357–364.
   PubMed Web of Science ®Google Scholar
• Inoue M, Kinne R, Tran T, Arias IM. (1982). Taurocholate transport by rat liver sinusoidal membrane vesicles: Evidence of sodium cotransport. Hepatology 2:572–579.
   PubMedGoogle Scholar
• International Transporter Consortium (2010). Membrane transporters in drug development. Nature Rev Drug Discov 9:215–236.
   PubMed Web of Science ®Google Scholar
• Ito K, Houston JB. (2005a). Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm Res 22:103–112.
   PubMed Web of Science ®Google Scholar
• Ito K, Hallifax D, Obach RS, Houston JB. (2005b). Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm. Drug Metab Dispos 33:837–844.
   PubMed Web of Science ®Google Scholar
• Ieiri I, Suwannakul S, Maeda K, Uchimaru H, Hashimoto K, Kimura M, Fujino H, Hirano M, Kusuhara H, Irie S, Higuchi S, Sugiyama Y. (2007). SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther 82:541–547.
   PubMed Web of Science ®Google Scholar
• Ishigami M, Honda T, Takasaki W, Ikeda T, Komai T, Ito K, Sugiyama Y. (2001). A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. Drug Metab Dispos 29:282–288.
   PubMed Web of Science ®Google Scholar
• Ishiguro N, Maeda K, Kishimoto W, Saito A, Harada A, Ebner T, Roth W, Igarashi T, Sugiyama Y. (2006). Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab Dispos 34:1109–1115.
   PubMed Web of Science ®Google Scholar
• Ishiguro N, Maeda K, Saito A, Kishimoto W, Matsushima S, Ebner T, Roth W, Igarashi T, Sugiyama Y. (2008). Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide. Drug Metab Dispos 36:796–805.
   PubMed Web of Science ®Google Scholar
• Jäger W, Gehring E, Hagenauer B, Aust S, Senderowicz A, Thalhammer T. (2003). Biliary excretion of flavopiridol and its glucuronides in the isolated perfused rat liver: Role of multidrug resistance protein 2 (Mrp2). Life Sci 73:2841–2854.
   PubMed Web of Science ®Google Scholar
• Jacobsen W, Kirchner G, Hallensleben K, Mancinelli L, Deters M, Hackbarth I, Benet LZ, Sewing KF, Christians U. (1999). Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab Dispos 27:173–179.
   PubMed Web of Science ®Google Scholar
• Jacobsen W, Kuhn B, Soldner A, Kirchner G, Sewing KF, Kollman PA, Benet LZ, Christians U. (2000). Lactonization is the critical first step in the disposition of the 50hydroxy-3-methylglutaryl-CoA reductase inhibitor atrorvastatin. Drug Metab Dispos 28:1369–1378.
   PubMed Web of Science ®Google Scholar
• Jones HM, Parrott N, Jorga K, Lavé T. (2006). A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet 45:511–542.
   PubMed Web of Science ®Google Scholar
• Kajosaari LI, Laitila J, Neuvonen PJ, Backman JT. (2005). Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: Effect of fibrates and rifampicin. Basic Clin Pharmacol Toxicol 97:249–256.
   PubMed Web of Science ®Google Scholar
• Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K. (2005). Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics 15:513–522.
   PubMed Web of Science ®Google Scholar
• Kanamitsu S, Ito K, Sugiyama Y. (2000). Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: Use of maximum unbound concentration of inhibitor at the inlet to the liver. Pharm Res 17:336–343.
   PubMed Web of Science ®Google Scholar
• Kantola T, Backman JT, Niemi M, Kivistö KT, Neuvonen PJ. (2000). Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol 56:225–229.
   PubMed Web of Science ®Google Scholar
• Kantola T, Kivistö KT, Neuvonen PJ. (1998). Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 64:58–65.
   PubMed Web of Science ®Google Scholar
• Katz DA, Carr R, Grimm DR, Xiong H, Holley-Shanks R, Mueller T, Leake B, Wang Q, Han L, Wang PG, Edeki T, Sahelijo L, Doan T, Allen A, Spear BB, Kim RB. (2006). Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics. Clin Pharmacol Ther 79:186–196.
   PubMed Web of Science ®Google Scholar
• Keppler D, Arias IM. (1997). Hepatic canalicular membrane. Introduction: Transport across the hepatocyte canalicular membrane. FASEB J 11:15–18.
   PubMed Web of Science ®Google Scholar
• Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M. (2009). ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 86:197–203.
   PubMed Web of Science ®Google Scholar
• Kimoto E, Chupka J, Xiao Y, Bi YA, Duignan DB. (2011). Characterization of digoxin uptake in sandwich-cultured human hepatocytes. Drug Metab Dispos 39:47–53.
   PubMed Web of Science ®Google Scholar
• Kindla J, Müller F, Mieth M, Fromm MF, König J. (2011). Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport. Drug Metab Dispos 39:1047–1053.
   PubMed Web of Science ®Google Scholar
• Kirby RS. (1998). Terazosin in benign prostatic hyperplasia: Effects on blood pressure in normotensive and hypertensive men. Br J Urol 82:373–379.
   PubMedGoogle Scholar
• Knauer MJ, Urquhart BL, Meyer zu Schwabedissen HE, Schwarz UI, Lemke CJ, Leake BF, Kim RB, Tirona RG. (2010). Human skeletal muscle drug transporters determine local exposure and toxicity of statins. Circ Res 106:297–306.
   PubMed Web of Science ®Google Scholar
• König J, Cui Y, Nies AT, Keppler D. (2000). Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Biol Chem 275:23161–23168.
   PubMed Web of Science ®Google Scholar
• König J. (2010). Uptake transporters of the human OATP family: Molecular characteristics, substrates, their role in drug–drug interactions, and functional consequences of polymorphisms. Drug Transporters, Springer Berlin Heidelberg. 201: 1–28.
   Google Scholar
• Kouzuki H, Suzuki H, Ito K, Ohashi R, Sugiyama Y. (1998). Contribution of sodium taurocholate co-transporting polypeptide to the uptake of its possible substrates into rat hepatocytes. J Pharmacol Exp Ther 286:1043–1050.
   PubMed Web of Science ®Google Scholar
• Kyrklund C, Backman JT, Kivistö KT, Neuvonen M, Laitila J, Neuvonen PJ. (2001). Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther 69:340–345.
   PubMed Web of Science ®Google Scholar
• Lam JL, Benet LZ. (2004). Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: Studies of digoxin metabolism in primary rat hepatocytes versus microsomes. Drug Metab Dispos 32:1311–1316.
   PubMed Web of Science ®Google Scholar
• Lam JL, Okochi H, Huang Y, Benet LZ. (2006a). In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: Characterizing the importance of transporter-enzyme interplay. Drug Metab Dispos 34:1336–1344.
   PubMed Web of Science ®Google Scholar
• Lam JL, Shugarts SB, Okochi H, Benet LZ. (2006b). Elucidating the effect of final-day dosing of rifampin in induction studies on hepatic drug disposition and metabolism. J Pharmacol Exp Ther 319:864–870.
   PubMed Web of Science ®Google Scholar
• Lau YY, Huang Y, Frassetto L, Benet LZ. (2007). effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther 81:194–204.
   PubMed Web of Science ®Google Scholar
• Li N, Nemirovskiy OV, Zhang Y, Yuan H, Mo J, Ji C, Zhang B, Brayman TG, Lepsy C, Heath TG, Lai Y. (2008). Absolute quantification of multidrug resistance-associated protein 2 (MRP2/ABCC2) using liquid chromatography tandem mass spectrometry. Anal Biochem 380:211–222.
   PubMed Web of Science ®Google Scholar
• Liu X, LeCluyse EL, Brouwer KR, Lightfoot RM, Lee JI, Brouwer KL. (1999). Use of Ca2+ modulation to evaluate biliary excretion in sandwich-cultured rat hepatocytes. J Pharmacol Exp Ther 289:1592–1599.
   PubMed Web of Science ®Google Scholar
• Lu C, Li P, Gallegos R, Uttamsingh V, Xia CQ, Miwa GT, Balani SK, Gan LS. (2006). Comparison of intrinsic clearance in liver microsomes and hepatocytes from rats and humans: Evaluation of free fraction and uptake in hepatocytes. Drug Metab Dispos 34:1600–1605.
   PubMed Web of Science ®Google Scholar
• Maeda K, Ieiri I, Yasuda K, Fujino A, Fujiwara H, Otsubo K, Hirano M, Watanabe T, Kitamura Y, Kusuhara H, Sugiyama Y. (2006). Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin Pharmacol Ther 79:427–439.
   PubMed Web of Science ®Google Scholar
• Matsushima S, Maeda K, Ishiguro N, Igarashi T, Sugiyama Y. (2008). Investigation of the inhibitory effects of various drugs on the hepatic uptake of fexofenadine in humans. Drug Metab Dispos 36:663–669.
   PubMed Web of Science ®Google Scholar
• Meier PJ, Eckhardt U, Schroeder A, Hagenbuch B, Stieger B. (1997). Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver. Hepatology 26:1667–1677.
   PubMed Web of Science ®Google Scholar
• Mikkaichi T, Suzuki T, Tanemoto M, Ito S, Abe T. (2004). The organic anion transporter (OATP) family. Drug Metab Pharmacokinet 19:171–179.
   PubMedGoogle Scholar
• Mück W, Ritter W, Ochmann K, Unger S, Ahr G, Wingender W, Kuhlmann J. (1997). Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin. Int J Clin Pharmacol Ther 35:255–260.
   PubMed Web of Science ®Google Scholar
• Müller M, Jansen PL. (1997). Molecular aspects of hepatobiliary transport. Am J Physiol 272:G1285–G1303.
   PubMed Web of Science ®Google Scholar
• Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T. (2004). Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther 75:415–421.
   PubMed Web of Science ®Google Scholar
• Nakagomi-Hagihara R, Nakai D, Kawai K, Yoshigae Y, Tokui T, Abe T, Ikeda T. (2006). OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker. Drug Metab Dispos 34:862–869.
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ, Niemi M, Backman JT. (2006). Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance. Clin Pharmacol Ther 80:565–581.
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Neuvonen M, Neuvonen PJ. (2003). Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: Potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 46:347–351.
   PubMed Web of Science ®Google Scholar
• Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, Backman JT, Kerb R, Schwab M, Neuvonen PJ, Eichelbaum M, Kivistö KT. (2004). High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 14:429–440.
   PubMedGoogle Scholar
• Niemi M, Kivistö KT, Hofmann U, Schwab M, Eichelbaum M, Fromm MF. (2005). Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br J Clin Pharmacol 59:602–604.
   PubMed Web of Science ®Google Scholar
• Niemi M, Pasanen MK, Neuvonen PJ. (2006). SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther 80:356–366.
   PubMed Web of Science ®Google Scholar
• Niemi M. (2010). Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ther 87:130–133.
   PubMed Web of Science ®Google Scholar
• Niemi M, Pasanen MK, Neuvonen PJ. (2011). Organic anion transporting polypeptide 1B1: A genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 63:157–181.
   PubMed Web of Science ®Google Scholar
• Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, Takane H, Irie S, Kusuhara H, Urasaki Y, Urae A, Higuchi S, Otsubo K, Sugiyama Y. (2003). Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 73:554–565.
   PubMed Web of Science ®Google Scholar
• Noé J, Portmann R, Brun ME, Funk C. (2007). Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos 35:1308–1314.
   PubMed Web of Science ®Google Scholar
• Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I. (2004). Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther 308:438–445.
   PubMed Web of Science ®Google Scholar
• Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P, Parkinson A. (2006). Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: Implications for drug-drug interactions. Drug Metab Dispos 34:191–197.
   PubMed Web of Science ®Google Scholar
• Olbricht C, Wanner C, Eisenhauer T, Kliem V, Doll R, Boddaert M, O’Grady P, Krekler M, Mangold B, Christians U. (1997). Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther 62:311–321.
   PubMed Web of Science ®Google Scholar
• Paine SW, Parker AJ, Gardiner P, Webborn PJ, Riley RJ. (2008). Prediction of the pharmacokinetics of atorvastatin, cerivastatin, and indomethacin using kinetic models applied to isolated rat hepatocytes. Drug Metab Dispos 36:1365–1374.
   PubMed Web of Science ®Google Scholar
• Park JW, Siekmeier R, Merz M, Krell B, Harder S, März W, Seidel D, Schüler S, Gross W. (2002). Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. Int J Clin Pharmacol Ther 40:439–450.
   PubMed Web of Science ®Google Scholar
• Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. (2006). SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 16:873–879.
   PubMed Web of Science ®Google Scholar
• Pasanen MK, Neuvonen PJ, Niemi M. (2008). Global analysis of genetic variation in SLCO1B1. Pharmacogenomics 9:19–33.
   PubMed Web of Science ®Google Scholar
• Petzinger E. (1994). Transport of organic anions in the liver. An update on bile acid, fatty acid, monocarboxylate, anionic amino acid, cholephilic organic anion, and anionic drug transport. Rev Physiol Biochem Pharmacol 123:47–211.
   PubMed Web of Science ®Google Scholar
• Pfefferkorn JA, Litchfield J, Hutchings R, Cheng XM, Larsen SD, Auerbach B, Bush MR, Lee C, Erasga N, Bowles DM, Boyles DC, Lu G, Sekerke C, Askew V, Hanselman JC, Dillon L, Lin Z, Robertson A, Olsen K, Boustany C, Atkinson K, Goosen TC, Sahasrabudhe V, Chupka J, Duignan DB, Feng B, Scialis R, Kimoto E, Bi YA, Lai Y, El-Kattan A, Bakker-Arkema R, Barclay P, Kindt E, Le V, Mandema JW, Milad M, Tait BD, Kennedy R, Trivedi BK, Kowala M. (2011). Discovery of novel hepatoselective HMG-CoA reductase inhibitors for treating hypercholesterolemia: A bench-to-bedside case study on tissue selective drug distribution. Bioorg Med Chem Lett 21:2725–2731.
   PubMedGoogle Scholar
• Poirier A, Funk C, Scherrmann JM, Lavé T. (2009). Mechanistic modeling of hepatic transport from cells to whole body: Application to napsagatran and fexofenadine. Mol Pharm 6:1716–1733.
   PubMed Web of Science ®Google Scholar
• Regazzi MB, Iacona I, Campana C, Gavazzi A, Viganò M, Perani G. (1994). Clinical efficacy and pharmacokinetics of HMG-CoA reductase inhibitors in heart transplant patients treated with cyclosporin A. Transplant Proc 26:2644–2645.
   PubMed Web of Science ®Google Scholar
• Regazzi MB, Iacona I, Campana C, Raddato V, Lesi C, Perani G, Gavazzi A, Viganò M. (1993). Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc 25:2732–2734.
   PubMed Web of Science ®Google Scholar
• Rostami-Hodjegan A, Tucker GT. (2007). Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 6:140–148.
   PubMed Web of Science ®Google Scholar
• Sasabe H, Terasaki T, Tsuji A, Sugiyama Y. (1997). Carrier-mediated hepatic uptake of quinolone antibiotics in the rat. J Pharmacol Exp Ther 282:162–171.
   PubMed Web of Science ®Google Scholar
• Search Collaborative Group (2008). SLCO1B1 variants and statin-induced myopathy− a genomewide study. N Engl J Med 359:789–799.
   PubMed Web of Science ®Google Scholar
• Seithel A, Glaeser H, Fromm MF, König J. (2008). The functional consequences of genetic variations in transporter genes encoding human organic anion-transporting polypeptide family members. Expert Opin Drug Metab Toxicol 4:51–64.
   PubMed Web of Science ®Google Scholar
• Shimizu M, Fuse K, Okudaira K, Nishigaki R, Maeda K, Kusuhara H, Sugiyama Y. (2005). Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab Dispos 33:1477–1481.
   PubMed Web of Science ®Google Scholar
• Shitara Y, Horie T, Sugiyama Y. (2006). Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci 27:425–446.
   PubMed Web of Science ®Google Scholar
• Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y. (2003). Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 304:610–616.
   PubMed Web of Science ®Google Scholar
• Shitara Y, Li AP, Kato Y, Lu C, Ito K, Itoh T, Sugiyama Y. (2003b). Function of uptake transporters for taurocholate and estradiol 17beta-D-glucuronide in cryopreserved human hepatocytes. Drug Metab Pharmacokinet 18:33–41.
   PubMedGoogle Scholar
• Shitara Y, Hirano M, Sato H, Sugiyama Y. (2004). Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: Analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 311:228–236.
   PubMed Web of Science ®Google Scholar
• Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, Windass AS, Schneck DW. (2004). Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 76:167–177.
   PubMed Web of Science ®Google Scholar
• Smith DA, Jones BC. (1992). Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochem Pharmacol 44:2089–2098.
   PubMed Web of Science ®Google Scholar
• Smith DA, Jones BC, Walker DK. (1996). Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics. Med Res Rev 16:243–266.
   PubMed Web of Science ®Google Scholar
• Smith NF, Figg WD, Sparreboom A. (2005). Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination. Expert Opin Drug Metab Toxicol 1:429–445.
   PubMedGoogle Scholar
• Soars MG, Grime K, Sproston JL, Webborn PJ, Riley RJ. (2007). Use of hepatocytes to assess the contribution of hepatic uptake to clearance in vivo. Drug Metab Dispos 35:859–865.
   PubMed Web of Science ®Google Scholar
• St-Pierre MV, Hagenbuch B, Ugele B, Meier PJ, Stallmach T. (2002). Characterization of an organic anion-transporting polypeptide (OATP-B) in human placenta. J Clin Endocrinol Metab 87:1856–1863.
   PubMed Web of Science ®Google Scholar
• Sultanpur C, Satyanarayana S, Reddy N, Kumar K, Kumar S. (2010). Drug-drug Interaction between Pravastatin and Gemfibrozil (Antihyperlipidemic) with Gliclazide (Antidiabetic) in Rats. J Young Pharm 2:152–155.
   PubMedGoogle Scholar
• Swift B, Pfeifer ND, Brouwer KL. (2010). Sandwich-cultured hepatocytes: An in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity. Drug Metab Rev 42:446–471.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Kim RB, Perry PR, Wilkinson GR. (1997). Characterization of the hepatic canalicular membrane transport of a model oligopeptide: Ditekiren. J Pharmacol Exp Ther 281:297–303.
   PubMedGoogle Scholar
• Tosco P Rolando B, Fruttero R, Henchoz Y, Martel S, Carrupt P-A, andandGasco A.(2008) Physicochemical profiling of sartans: A detailed study of ioization constants and distribution coefficients. Helvetica Chimica Acta 91:2379–2398.
   Google Scholar
• Treiber A, Schneiter R, Häusler S, Stieger B. (2007). Bosentan is a substrate of human OATP1B1 and OATP1B3: Inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos 35:1400–1407.
   PubMed Web of Science ®Google Scholar
• van Giersbergen PL, Halabi A, Dingemanse J. (2002). Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole. Br J Clin Pharmacol 53:589–595.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Kusuhara H, Maeda K, Shitara Y, Sugiyama Y. (2009a). Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther 328:652–662.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Maeda K, Kondo T, Nakayama H, Horita S, Kusuhara H, Sugiyama Y. (2009b). Prediction of the hepatic and renal clearance of transporter substrates in rats using in vitro uptake experiments. Drug Metab Dispos 37:1471–1479.
   PubMed Web of Science ®Google Scholar
• Weber C, Schmitt R, Birnboeck H, Hopfgartner G, van Marle SP, Peeters PA, Jonkman JH, Jones CR. (1996). Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther 60:124–137.
   PubMed Web of Science ®Google Scholar
• Werner D, Werner U, Meybaum A, Schmidt B, Umbreen S, Grosch A, Lestin HG, Graf B, Zolk O, Fromm MF. (2008). Determinants of steady-state torasemide pharmacokinetics: Impact of pharmacogenetic factors, gender and angiotensin II receptor blockers. Clin Pharmacokinet 47:323–332.
   PubMed Web of Science ®Google Scholar
• White EP, Pimprale S, Yu Z, Ketty V, Bourgea J, Patten CJ, Crespi C and Xiao G. (2006) Cloning and characterization of cynomolgus monkey and rhesus monkey organic anion transporting poloypeptide 1B3 and comparison of their function with human OATP-1B3. AAPS Annual meeting and exposition.
   Google Scholar
• Wienen W, Entzeroth M, van Meel JCA, Stangier J, Busch U, Ebher T, Schmid J, Lehmann H, Matzek K, Kempthorne-Rawson Gladigau, V, Hauel NH. (2000) A review on telmisartan: A novel long-acting angiotensin II receptor antagonist. Cardiovascular Drug Rev 18:127–154.
   Google Scholar
• Wu CY, Benet LZ. (2005). Predicting drug disposition via application of BCS: Transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22:11–23.
   PubMed Web of Science ®Google Scholar
• Xiong H, Carr RA, Locke CS, Katz DA, Achari R, Doan TT, Wang P, Jankowski JR, Sleep DJ. (2007). Dual effects of rifampin on the pharmacokinetics of atrasentan. J Clin Pharmacol 47:423–429.
   PubMed Web of Science ®Google Scholar
• Yamada A, Maeda K, Kamiyama E, Sugiyama D, Kondo T, Shiroyanagi Y, Nakazawa H, Okano T, Adachi M, Schuetz JD, Adachi Y, Hu Z, Kusuhara H, Sugiyama Y. (2007). Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos 35:2166–2176.
   PubMed Web of Science ®Google Scholar
• Yamazaki M, Suzuki H, Hanano M, Tokui T, Komai T, Sugiyama Y. (1993). Na(+)-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. Am J Physiol 264:G36–G44.
   PubMed Web of Science ®Google Scholar
• Yamazaki M, Akiyama S, Nishigaki R, Sugiyama Y. (1996). Uptake is the rate-limiting step in the overall hepatic elimination of pravastatin at steady-state in rats. Pharm Res 13:1559–1564.
   PubMed Web of Science ®Google Scholar
• Yamazaki M, Suzuki H, Sugiyama Y. (1996). Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. Pharm Res 13:497–513.
   PubMed Web of Science ®Google Scholar
• Yasar U, Forslund-Bergengren C, Tybring G, Dorado P, Llerena A, Sjöqvist F, Eliasson E, Dahl ML. (2002). Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther 71:89–98.
   PubMed Web of Science ®Google Scholar
• Yamashiro W, Maeda K, Hirouchi M, Adachi Y, Hu Z, Sugiyama Y. (2006). Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab Dispos 34:1247–1254.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang Y, Huang SM. (2009). Scientific and regulatory perspectives on metabolizing enzyme-transporter interplay and its role in drug interactions: Challenges in predicting drug interactions. Mol Pharm 6:1766–1774.
   PubMed Web of Science ®Google Scholar